Progression-free survival was significantly longer in the bevacizumab and capecitabine group than in the bevacizumab only group ( median @ months -LSB- @ % CI @-@ -RSB- vs @ months -LSB- @-@ -RSB- ; stratified hazard ratio @ -LSB- @ % CI @-@ -RSB- ; two-sided log-rank p < @ ) , as was overall survival ( median @ months -LSB- @ % CI @-not reached -RSB- vs @ months -LSB- @-@ -RSB- ; stratified HR @ -LSB- @ % CI @-@ -RSB- ; two-sided log-rank p = @ ) .